Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial

BACKGROUND: The use of IL-6 blockers in COVID-19 hospitalized patients has been associated with a reduction in mortality compared to standard care. However, many uncertainties remain pertaining to optimal intervention time, administration schedule, and predictors of response. To date, data on the us...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Vicuña, Rosario, Rodriguez-García, Sebastián C., Abad-Santos, Francisco, Bautista Hernández, Azucena, García-Fraile, Lucio, Barrios Blandino, Ana, Gutiérrez Liarte, Angela, Alonso-Pérez, Tamara, Cardeñoso, Laura, Alfranca, Aránzazu, Mejía-Abril, Gina, Sanz Sanz, Jesús, González-Alvaro, Isidoro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904894/
https://www.ncbi.nlm.nih.gov/pubmed/35280907
http://dx.doi.org/10.3389/fmed.2022.819621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904894/
https://www.ncbi.nlm.nih.gov/pubmed/35280907
http://dx.doi.org/10.3389/fmed.2022.819621

Ejemplares similares